NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free CMMB Stock Alerts $0.64 -0.02 (-3.03%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.62▼$0.6550-Day Range$0.59▼$0.8652-Week Range$0.42▼$1.89Volume23,560 shsAverage Volume27,681 shsMarket Capitalization$7.07 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Chemomab Therapeutics alerts: Email Address Chemomab Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside993.9% Upside$7.00 Price TargetShort InterestHealthy1.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.20) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.91 out of 5 stars 3.3 Analyst's Opinion Consensus RatingChemomab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChemomab Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.31% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently decreased by 29.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMMB. Previous Next 2.5 News and Social Media Coverage News SentimentChemomab Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CMMB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chemomab Therapeutics are expected to decrease in the coming year, from ($1.20) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Chemomab Therapeutics Stock (NASDAQ:CMMB)Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Read More CMMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMMB Stock News HeadlinesApril 24, 2024 | globenewswire.comChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateApril 18, 2024 | globenewswire.comChemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 8, 2024 | finance.yahoo.comChemomab Therapeutics Ltd. (CMMB)April 2, 2024 | globenewswire.comChemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024March 25, 2024 | globenewswire.comChemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisMarch 7, 2024 | investorplace.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023March 7, 2024 | finanznachrichten.deChemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 7, 2024 | finance.yahoo.comChemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 5, 2024 | prnewswire.comChemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceFebruary 20, 2024 | msn.comBiotech Shares Massively Bid Up Before Opening BellFebruary 20, 2024 | finance.yahoo.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 20, 2024 | prnewswire.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 14, 2024 | finance.yahoo.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 14, 2024 | prnewswire.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 5, 2024 | finance.yahoo.comChemomab Therapeutics to Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comChemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisJanuary 6, 2024 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comChemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024December 29, 2023 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB) Insider TradesDecember 21, 2023 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB), Analyst Ratings, Price Targets, PredictionsDecember 6, 2023 | msn.comHere's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock NowNovember 16, 2023 | finance.yahoo.comChemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNovember 15, 2023 | markets.businessinsider.comUS Stocks Gain; Producer Prices Fall In OctoberNovember 15, 2023 | markets.businessinsider.comChemomab Reports Fast Track Designation For CM-101 - Quick FactsNovember 15, 2023 | msn.comWhy is Liver Disease Focused Chemomab Stock Trading Higher Today?See More Headlines Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/27/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMMB CUSIPN/A CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+993.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-114.00% Return on Assets-88.53% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book0.42Miscellaneous Outstanding Shares11,050,000Free Float9,734,000Market Cap$7.07 million OptionableNot Optionable Beta0.36 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Adi Mor George Ph.D. (Age 42)Co-Founder, Chief Scientific Officer, CEO & Executive Director Comp: $330kMs. Sigal Fattal CPA (Age 53)M.B.A., Chief Financial Officer Comp: $322kDr. Matthew B. Frankel M.B.A. (Age 55)M.D., Chief Medical Officer & VP of Drug Development Comp: $850kBarbara LindheimConsulting Vice President of Investor & Public Relations, Strategic CommunicationsKey CompetitorsPasithea TherapeuticsNASDAQ:KTTAKinetaNASDAQ:KABionomicsNASDAQ:BNOXGraybug VisionNASDAQ:GRAYTFF PharmaceuticalsNASDAQ:TFFPView All Competitors CMMB Stock Analysis - Frequently Asked Questions Should I buy or sell Chemomab Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CMMB shares. View CMMB analyst ratings or view top-rated stocks. What is Chemomab Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 1 year price targets for Chemomab Therapeutics' shares. Their CMMB share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 993.9% from the stock's current price. View analysts price targets for CMMB or view top-rated stocks among Wall Street analysts. How have CMMB shares performed in 2024? Chemomab Therapeutics' stock was trading at $0.51 on January 1st, 2024. Since then, CMMB stock has increased by 25.5% and is now trading at $0.6399. View the best growth stocks for 2024 here. Are investors shorting Chemomab Therapeutics? Chemomab Therapeutics saw a drop in short interest in April. As of April 15th, there was short interest totaling 155,800 shares, a drop of 29.8% from the March 31st total of 221,900 shares. Based on an average daily trading volume, of 217,000 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.3% of the shares of the stock are sold short. View Chemomab Therapeutics' Short Interest. When is Chemomab Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CMMB earnings forecast. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. (NASDAQ:CMMB) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.14. During the same period last year, the business posted ($0.72) earnings per share. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMMB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
